Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recurrence Rate in Wet AMD Patients on 3-Month Ranibizumab
NCT01453920Phase 4Completed
- Sponsor
- University Health Network
- Start
- Nov 2011
- Primary completion
- Jul 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by University Health Network. Started Nov 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01453920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453920.